Senestech Inc is a biotechnology company focused on the development of innovative solutions for pest control through its proprietary platform that employs the principles of biology and technology
The company's primary aim is to create environmentally friendly products that effectively manage pest populations while minimizing harmful impacts on non-target species and ecosystems. By utilizing a unique approach to target specific species, Senestech seeks to meet the growing demand for sustainable pest management solutions in various agricultural and residential markets.
With no direct competition in the fertility control space and growing demand for non-lethal rodent management, could SNES be the next big winner? Find out in this deep-dive conversation with CEO Joel Fruendt.
SenesTech is a small company with an innovative way for rodent control using induced infertility. They have rapidly expanded with pilot programs in major US cities and also globally in New Zealand and Australia.
SenesTech's Evolve products are recent, but take a novel approach to rodent plagues, painlessly reducing reproduction velocity and the product is already taking off with huge distribution deals in place and rapidly improving company financials.
SenesTech (NASDAQ:SNES) reported a 51% increase in revenue for the first nine months of 2024, totaling $1.4 million, driven by strong sales of its Evolve Rat and Evolve Mouse products. Gross margins improved to 65% in Q3 2024, up from 49% in the same quarter last year, due to enhanced manufacturing efficiency. The company’s operating expenses decreased by 12%, and its adjusted EBITDA loss was the smallest in its history, reducing cash burn by 21%. Evolve Rat, launched in early 2024, now accounts for 52% of Q3 revenue, and the company has expanded sales through e-commerce platforms like Amazon and Walmart. Additionally, SenesTech is expanding into international markets, securing significant orders from distributors in Hong Kong and the Netherlands. The company is also exploring municipal opportunities, including a rat contraception pilot program in New York City.
SenesTech (NASDAQ: SNES), the leader in birth control to manage rodent pest populations, is reporting that the New York City Council has approved a bill to implement a rat contraception pilot program. According to the announcement, the bill stipulates that “rat contraceptive” means an agent for the reduction of reproductive capacity in rats; the bill also calls for the use of an agent approved by the U.S. Environment Protection Agency (“EPA”). Currently, SenesTech is the only manufacturer of products that meet this requirement. The bill calls for city departments to begin the program, which will run for at least 12 months in two rat-mitigation zones and a comparable area, within 180 days of enactment.
SenesTech (NASDAQ: SNES), the rodent fertility-control experts and inventors of the only EPA-registered contraceptive for male and female rats, will be spotlighted at the upcoming Lytham Partners Fall 2024 Investor Conference. Company officials are slated to participate in a webcast presentation during the event, which will be held Oct. 1, 2024; the company’s presentation is scheduled to begin at 11 a.m. ET. In addition, SenesTech representatives will host online one-on-one meetings with investors during the virtual conference.
SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, recently issued new unregistered warrants to purchase up to an aggregate of 1,011,004 shares of common stock at $4.35 per unit in a private placement. The company also closed on an exercise of certain existing warrants to purchase 505,502 shares of its common stock at a reduced exercise price of $4.60 per unit, raising approximately $2.3 million in aggregate gross proceeds. SenesTech intends to use the net proceeds from this transaction for working capital and general corporate purposes ( https://ibn.fm/o12H7 ).
SenesTech (NASDAQ: SNES), the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, has closed on an exercise of certain existing warrants. The exercise consisted of purchasing 505,502 shares of the company’s common stock at a reduced exercise price of $4.60 per share. The company also issued new warrants. According to the announcement, gross proceeds from the exercise of the existing warrants totaled an estimated $2.3 million before fees and deductions. The company plans to use the funds from the transaction for working capital and general corporate purposes, including the continued rollout of its Evolve(R) product line. H.C. Wainwright acted as the exclusive placement agent for the transaction.
SenesTech (NASDAQ: SNES), the inventor of ContraPest(R), the only U.S. EPA-registered contraceptive for male and female rats, as well as Evolve(R) and Evolve Mouse(R), EPA-designated minimum risk contraceptives for rodents, recently reported financial results for its second quarter of fiscal 2024, ended June 30, 2024. In addition, Joel Fruendt, President and CEO of SenesTech, and Tom Chesterman, CFO of SenesTech, hosted a conference call ( https://ibn.fm/1MQaT ).
SenesTech’s (NASDAQ: SNES) flagship product, Evolve(TM), has repeatedly demonstrated an effective rat control alternative to current market offerings. “The active ingredient in the product has been scientifically proven to reduce rodent fertility, ultimately offering a more proactive approach to addressing the growing rat problem, as opposed to a more reactive approach, as is the case with poisons and traps. The obvious argument is that it’s better to control reproduction than to kill rats after they are born,” reads a recent article.
In 2023, it was estimated that New York City had roughly 3 million rats, an increase of almost 1 million over the last ten years. The situation has gotten so bad that the city has become almost synonymous with rat infestation problems.
SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations and the only manufacturer of commercially available, EPA-registered Rat Birth Control(R), is reporting on its second-quarter 2024 financial results. According to the report, the company saw record revenue of $874,000 in the first half of 2024, a 62% increase when compared to the first half of 2023, as well as improvement in margin percentages.
